837404-68-9

Upstream product

• 1548-13-6 p-trifluoromethyl-phenylisocyanate 
• 891031-10-0 tert-butyl 4-[3-(2-chlorobenzyl)-7-hydroxy-3H-[1,2,3]triazole[4,5-d]pyrimidin-5-yl]-1-piperidinecarboxylate 
• 63777-70-8 2-chlorobenzylazide 
• 611-19-8 1-chloro-2-(chloromethyl)benzene 
• 74702-40-2 N-(4-(trifluoromethyl)phenyl)formamide 

Relevant academic research and scientific papers

GPR17-MODULATING COMPOUNDS, DIAGNOSTIC AND THERAPEUTIC USES THEREOF

Disclosed are compounds able to modulate the activity of the GPR17 receptor in a highly specific way, which are useful in the treatment and diagnosis of diseases or dysfunctions involving the activation of said receptor. In particular, the compounds according to the invention can be used for neuroprotective and/or reparatory purposes, in cerebral, cardiac and renal ischaemia, in cerebral trauma, in chronic neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), and in demyelinating diseases such as multiple sclerosis.

GPR17-MODULATING COMPOUNDS, DIAGNOSTIC AND THERAPEUTIC USES THEREOF

Disclosed are compounds able to modulate the activity of the GPR17 receptor in a highly specific way, which are useful in the treatment and diagnosis of diseases or dysfunctions involving the activation of said receptor. In particular, the compounds accor